Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13096894 | 0.84 | EGFR (0.38) | LTA4HEPHX2FFAR1MMP13BCHE | |
| SCHEMBL13106624 | 0.82 | ELOVL1 (0.46) | ELOVL1 | |
| SCHEMBL13096892 | 0.82 | ELOVL1 (0.47) | LTA4HELOVL1 | |
| SCHEMBL3091177 | 0.80 | TDP1 (0.38) | — | |
| SCHEMBL13097551 | 0.77 | CYP2D6 (0.53) | LTA4HEPHX2ELOVL1 | |
| SCHEMBL21538309 | 0.70 | GABRG2 (0.41) | — | |
| SCHEMBL20319007 | 0.70 | HTT (0.42) | MAOB | |
| SCHEMBL13531399 | 0.70 | CYP1A2 (0.55) | LTA4HMAOBBCHE | |
| SCHEMBL16976018 | 0.68 | MAOB (0.64) | LTA4HEPHX2FFAR1FFAR4MAOB | |
| SCHEMBL4407617 | 0.68 | ENPP2 (0.62) | LTA4HEPHX2FFAR1FFAR4MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | LTA4H 421/4885EPHX2 640/4885FFAR1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.